glp-1 alzheimer's clinical trials Novo Nordisk justifies reasoning behind failed GLP-1R agonists protect against Alzheimer's

17 , CD011014 (2016)

Mol Cell 2016;61:520-34

FIGURE 3 3.7 Microbial-GBA disorders The gastrointestinal system interacts with the brain in a reciprocal relationship known as the GBA

Another aspect of the invention is to provide a method for administering two agents, such as administering two agents sequentially, for treatment of sexual dysfunction, wherein each agent is administered by a different route, utilizing a peptide-based melanocortin receptor agonist administered by a non-oral route, such as nasal delivery, and a PDE-5 inhibitor that is a small molecule administered by an oral route

these are not immunity or vitamin boosters for healthy people